What’s the current market cap for Privia Health Group stock?

Privia Health Group (PRVA) has a market cap of $2.7B as of May 31, 2026.

What is the P/E ratio for Privia Health Group stock?

The price to earnings (P/E) ratio for Privia Health Group (PRVA) stock is 126.87 as of May 31, 2026.

Does Privia Health Group stock pay dividends?

No, Privia Health Group (PRVA) stock does not pay dividends to its shareholders as of May 31, 2026.

When is the next Privia Health Group dividend payment date?

Privia Health Group (PRVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Privia Health Group?

Privia Health Group (PRVA) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Privia Health Group stock | $PRVA Share Price

13:30

15:10

16:45

18:25

20:00

About Privia Health Group

Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.

Ticker

$PRVA

Sector

Health

Primary listing

NASDAQ

Employees

1,226

Headquarters

Arlington, United States

Website

www.priviahealth.com

PRVA Metrics

BasicAdvanced

$2.7bn

126.87

$0.17

0.97

What the Analysts think about PRVA

Analyst ratings (Buy, Hold, Sell) for Privia Health Group stock.

Bulls say / Bears say

Q1 revenue increased 25.8% year-over-year to $603.8 million, beating consensus expectations and reflecting solid same-store growth and new provider additions—driving a 15% gain in practice collections and a 27% rise in attributed lives (Reuters).

Adjusted EPS of $0.19 beat analyst forecasts of $0.07, and adjusted EBITDA rose 36.3% to $36.7 million, demonstrating operating leverage under Privia’s physician-enablement model (Reuters).

Management raised full-year guidance for attributed lives to 1.60–1.625 million and kept revenue guidance at $2.35–$2.45 billion, aiming for roughly 80% free-cash-flow conversion of adjusted EBITDA—underscoring confidence in continued growth (Reuters).

GAAP net income for Q1 was just $3.1 million, representing a net profit margin of around 0.5%, highlighting ongoing challenges in translating strong revenue growth into meaningful bottom-line results (Investing.com).

Gross profit margin was only 9.87% in Q1, reflecting thin operating profitability and exposing Privia’s care-delivery platform to cost pressures (Investing.com).

Shares are trading at a trailing P/E of about 125 times earnings, a high valuation that allows little margin for error if operational or profitability improvements take longer than investors expect (Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

PRVA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

PRVA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRVA

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Adjusted EPS of $0.19 beat analyst forecasts of $0.07, and adjusted EBITDA rose 36.3% to $36.7 million, demonstrating operating leverage under Privia’s physician-enablement model (Reuters).

Gross profit margin was only 9.87% in Q1, reflecting thin operating profitability and exposing Privia’s care-delivery platform to cost pressures (Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.